期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

^(18)F-FDG PET/CT SUV值与胰腺癌预后的相关性研究

Correlation of ^(18)F-FDG PET/CT SUV max value with prognosis in pancreatic cancer
下载PDF
导出
摘要 目的探讨胰腺癌组织18F-FDG PET/CT SUV摄取值与肿瘤预后的关系。方法回顾性分析我院2009年10月~2011年12月期间接受18F-FDG PET/CT检查的37例胰腺癌患者资料,测量其SUVmax摄取值。以SUVmax值3.5为分界点,将患者分为两组。采用Kaplan-Meier法绘制生存曲线并判断SUVmax值对胰腺癌预后的影响。结果 SUVmax≥3.5患者的生存时间明显低于SUVmax<3.5患者(P<0.001)。结论胰腺癌组织的18F-FDG PET/CT SUV摄取值与肿瘤的预后密切相关。 Objective To study the relationship between the 18 F-FDG PET/CT imaging standard uptake value （SUV） and prognosis in pancreatic cancer. Methods 37 cases of pancreatic cancer patients in our hospital between October 2009 and De- cember 2011 with complete data were retrospectively analyzed . The PET/CT SUV value was recorded. All patients were divided into two groups depending on the demarcation point of SUV values of 3.5. Kaplan-Meier model was used to study the factors influ- encing the prognosis of patients with pancreatic cancer. Results Single factor analysis revealed that the negative correlation was found between the SUV value and life cycle. Patients＇ SUV values smaller than 3.5. were related to long-term survival rate （P 〈 0. 001 ）. Conclusion 18F-FDG PET/CT SUV value is the key to prognosis of pancreatic cancer patients.
作者 陈正君 陈跃 张伟
机构地区 泸州医学院附属医院影像科
出处 《四川医学》 CAS 2013年第9期1436-1438,共3页 Sichuan Medical Journal
关键词 胰腺癌 发射型计算机体层显像 标准摄取值 生存评价 预后 pancreatic cancer PET SUV survival evaluation prognostic
分类号 R735.9 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Izuishi K,Yamamoto Y,Sano T,et al. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer [ J ]. Gastrointest Surg,2010,14 (7) : 1151.
  • 2Maemura K, Takao S, Shinehi H, et al. Role of positron emission tomo- graphy in decisions on treatment strategies for pancreatic cancer [ J ]. Hepatobiliary Pancreat Surg,2006,13 (5) : 435.
  • 3张雯杰,吴宁.^(18)F-FDG PET-CT在胰腺癌中的作用[J].癌症进展,2011,9(3):233-236. 被引量：4
  • 4Kuwatani M, Kawakami H, Eto K,et al. Modalities for evaluating che- motherapeutic efficacy and survival time in patients with advanced pan- creatic cancer: Comparison between FDG-PET, CT, and serum tumor markers[J]. Intern Med,2009,48 ( 11 ) :867.
  • 5Choi M, Heilbrun LK, Venkatramanamoorthy R, et al. Using ^18F-flu- orodeoxyglucose positron emission tomography to monitor c.linical out- comes in patients treated with neoadjuvant chemo-radiotherapy for lo- cally advanced pancreatic cancer [ J ]. Am J Clin Oncol, 2010, 33 (3) : 257.
  • 6Padak C, Topkan E, Onal C ,et al. Prognostic value of gross tumor vol- ume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemo- radiotherapy[J]. Radiat Oncol, 2012, 19(7) :37.
  • 7Hutchinson L. Imaging: PET is prognostic of survival in pancreatic cancer patients[J]. Nat Rev Clin Oncol, 2010,7(10) :551.
  • 8Lyshchik A, Higashi T, Nakamoto Y,et al. Dual-phase ^18F-fluoro- 2-deoxy-D-glucose positron emission tomography as a prognostic param- eter in patients with pancreatic cancer[J]. Eur J Nucl Med Mol Imaging,2005,32 (4) :389 - 397.
  • 9Mataki Y, Shinchi H, Kurahara H, et al. Clinical usefulness of FDG-PET for pancreatic cancer[ J]. Gan To Kagaku Ryoho, 2009,36 ( 13 ) :2516 - 2520.
  • 10Zimny M, Fass J, Bares R, et al. Fluorodeoxyglucose positron emis- sion tomography and the prognosis of pancreatic carcinoma[ J ]. Scand J Gastroenterol, 2000,35 ( 8 ) :883 - 888.

二级参考文献4

共引文献3

四川医学
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部